Cargando…

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer

BACKGROUND: Acute exacerbation of interstitial lung disease (AE-ILD) is the most serious complication in lung cancer patients with pre-existing ILD receiving chemotherapy. The role of vascular endothelial growth factor (VEGF) in pathogenesis of AE-ILD is conflicting. The influence of bevacizumab (Be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamada, Shohei, Ichiyasu, Hidenori, Ikeda, Tokunori, Inaba, Megumi, Kashiwabara, Kosuke, Sadamatsu, Tomoki, Sato, Nahoko, Akaike, Kimitaka, Okabayashi, Hiroko, Saruwatari, Koichi, Tomita, Yusuke, Saeki, Sho, Hirata, Naomi, Yoshinaga, Takeshi, Fujii, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446385/ https://www.ncbi.nlm.nih.gov/pubmed/30940113 http://dx.doi.org/10.1186/s12890-019-0838-2

Ejemplares similares

Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with Pneumocystis pneumonia
por: Hamada, Shohei, et al.
Publicado: (2020)

Clinical impact of SUV(max) of interstitial lesions in lung cancer patients with interstitial lung disease who underwent pulmonary resection
por: Akaike, Kimitaka, et al.
Publicado: (2022)

Interstitial Lung Disease in Adulthood Associated with Surfactant Protein C Gene Mutation in a Patient with a History of Lipoid Pneumonia in Infancy
por: Furukawa, Tsuguhiro, et al.
Publicado: (2023)

Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer
por: Imamura, Kosuke, et al.
Publicado: (2022)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
por: Sato, Ryo, et al.
Publicado: (2019)

Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors
por: Tomita, Yusuke, et al.
Publicado: (2022)

Pembrolizumab-related Immune Thrombocytopenia in a Patient with Lung Adenocarcinoma Treated by Radiotherapy: Potential Immune-related Adverse Event Elicited by Radiation Therapy
por: Tamanoi, Daisuke, et al.
Publicado: (2021)

Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab Treatment
por: Nakashima, Kei, et al.
Publicado: (2020)

Acute Exacerbation of Idiopathic Interstitial Pneumonia in a Patient with Hepatocellular Carcinoma after Transcatheter Arterial Therapy Using Miriplatin
por: Kakiuchi, Yosuke, et al.
Publicado: (2019)

Validation of a breath-holding test as a screening test for exercise-induced hypoxemia in chronic respiratory diseases
por: Ideguchi, Hideharu, et al.
Publicado: (2021)

A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti‐PD‐1 immune checkpoint antibody in a lung cancer patient
por: Jodai, Takayuki, et al.
Publicado: (2018)

Primary lung sebaceous carcinoma successfully treated with radiotherapy and pembrolizumab: A case report
por: Jodai, Yasumiko, et al.
Publicado: (2022)

Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumonias
por: Okabayashi, Hiroko, et al.
Publicado: (2017)

Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells
por: Tenjin, Yuki, et al.
Publicado: (2019)

A Case of Biphasic Pulmonary Blastoma Treated with Carboplatin and Paclitaxel plus Bevacizumab
por: Sakata, Shinya, et al.
Publicado: (2015)

Airway Pseudomonas aeruginosa density in mechanically ventilated patients: clinical impact and relation to therapeutic efficacy of antibiotics
por: Migiyama, Yohei, et al.
Publicado: (2021)

Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: Successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy
por: Ichiyasu, Hidenori, et al.
Publicado: (2016)

Successful treatment with dupilumab for mucus plugs in severe asthma
por: Anai, Moriyasu, et al.
Publicado: (2022)

The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients
por: Saruwatari, Koichi, et al.
Publicado: (2019)

Decrease in hemoglobin level predicts increased risk for severe respiratory failure in COVID-19 patients with pneumonia
por: Anai, Moriyasu, et al.
Publicado: (2021)

(18)F‐FDG uptake in accessory respiratory muscles shows the respiratory effort of patients with pleuroparenchymal fibroelastosis
por: Okabayashi, Hiroko, et al.
Publicado: (2022)

Efficacy of direct hemoperfusion using polymyxin B-immobilized fiber column (PMX-DHP) in rapidly progressive interstitial pneumonias: results of a historical control study and a review of previous studies
por: Ichiyasu, Hidenori, et al.
Publicado: (2017)

Comparison of oncological outcomes between trisegmentectomy and lobectomy for non-small cell lung cancer in the left upper division
por: Nishikubo, Megumi, et al.
Publicado: (2022)

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
por: Stinchcombe, Thomas E
Publicado: (2007)

Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC)
por: Chien, Chun-Ru, et al.
Publicado: (2012)

Intracameral bevacizumab administered for non-small cell lung cancer metastasis to iris
por: Schell, Jonathan C., et al.
Publicado: (2011)

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
por: Xiao, Xian, et al.
Publicado: (2022)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Population pharmacokinetic modeling of PF-06439535 (a bevacizumab biosimilar) and reference bevacizumab (Avastin(®)) in patients with advanced non-squamous non-small cell lung cancer
por: Li, Cheryl S. W., et al.
Publicado: (2019)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Bevacizumab treatment for advanced non-small cell lung cancer: A case report
por: FAN, YUN, et al.
Publicado: (2013)

Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
por: Martino, EC, et al.
Publicado: (2016)

Re-188 Enhances the Inhibitory Effect of Bevacizumab in Non-Small-Cell Lung Cancer
por: Xiao, Jie, et al.
Publicado: (2016)

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non‐Small Cell Lung Cancer
por: Schneider, Benjamin K., et al.
Publicado: (2019)

Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases
por: Ascha, Mustafa S., et al.
Publicado: (2019)

Societal savings in patients with advanced non-squamous non-small-cell lung cancer receiving bevacizumab-based versus non-bevacizumab-based treatments in France, Germany, Italy, and Spain
por: Lister, Johanna, et al.
Publicado: (2012)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST)
por: Tanaka, Shiro, et al.
Publicado: (2011)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lovrqtlqplgk6sfpmju1gs9d6r